Company Description
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States.
Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification.
The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics.
It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Charles L. Pope CPA |
Contact Details
Address: 1990 Main Street, Suite 750 Sarasota, Florida 34236 United States | |
| Phone | (813) 286-7900 |
| Website | oragenics.com |
Stock Details
| Ticker Symbol | OGEN |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001174940 |
| CUSIP Number | 684023500 |
| ISIN Number | US6840235005 |
| Employer ID | 59-3410522 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Charles L. Pope CPA | Executive Chairman |
| Joseph Michael Redmond | President and Interim Principal Executive Officer |
| Janet Huffman | Chief Financial Officer, Secretary and Treasurer |
| Dr. James P. Kelly M.A., M.D. | Chief Medical Officer and Member of Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 10, 2024 | 8-K | Current Report |
| Jun 26, 2024 | 8-K | Current Report |
| Jun 25, 2024 | 424B5 | Filing |
| Jun 25, 2024 | 424B5 | Filing |
| Jun 20, 2024 | 8-K | Current Report |
| May 23, 2024 | 8-K | Current Report |
| May 22, 2024 | 8-K | Current Report |
| May 17, 2024 | 8-K | Current Report |
| May 16, 2024 | 8-K | Current Report |
| May 15, 2024 | 10-Q | Quarterly Report |